- Previous Close
2.0700 - Open
2.0700 - Bid 1.9040 x --
- Ask 2.0050 x --
- Day's Range
2.0700 - 2.0700 - 52 Week Range
1.8860 - 3.8550 - Volume
0 - Avg. Volume
0 - Market Cap (intraday)
37.497M - Beta (5Y Monthly) 2.61
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3700 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Molecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH. It also develops OATD-02, an arginase 1 and arginase 2, which is in Phase I clinical trial for the treatment of cancer; USP7, USP21, and YKL-40 for the treatment of cancer; and Deubiquitinase program. The company was formerly known as OncoArendi Therapeutics S.A. and changed its name to Molecure S.A. in March 2022. Molecure S.A. was founded in 2012 and is headquartered in Warsaw, Poland.
molecure.comRecent News: 1B1.F
View MorePerformance Overview: 1B1.F
Trailing total returns as of 4/7/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1B1.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1B1.F
View MoreValuation Measures
Market Cap
41.57M
Enterprise Value
38.98M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.71
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-15.15%
Return on Equity (ttm)
-25.19%
Revenue (ttm)
1.52M
Net Income Avi to Common (ttm)
-30.75M
Diluted EPS (ttm)
-0.3700
Balance Sheet and Cash Flow
Total Cash (mrq)
28.58M
Total Debt/Equity (mrq)
6.94%
Levered Free Cash Flow (ttm)
-47.12M